Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
Thomas Wiesner, Ping Chi(Memorial Sloan Kettering Cancer Center), Charlotte E. Ariyan(Memorial Sloan Kettering Cancer Center), Shipra Shukla(Memorial Sloan Kettering Cancer Center), Gary K. Schwartz(Baylor University Medical Center), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Zhen Cao(Memorial Sloan Kettering Cancer Center), Iñigo Landa(Inserm), Julia Button(Memorial Sloan Kettering Cancer Center), Klaus J. Busam(Memorial Sloan Kettering Cancer Center), Wenhuo Hu(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Dong Gao(Shenzhen Bay Laboratory), Nathalie Lailler(Memorial Sloan Kettering Cancer Center), Sasinya N. Scott(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Andrea Sboner(Cornell University), Ronak Shah(Memorial Sloan Kettering Cancer Center), Travis J. Hollmann(Bristol-Myers Squibb (United States)), Deyou Zheng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rajmohan Murali(Memorial Sloan Kettering Cancer Center), Qi Fan Zhang(Memorial Sloan Kettering Cancer Center), Elissa W.P. Wong(Memorial Sloan Kettering Cancer Center), Laetitia Borsu(Memorial Sloan Kettering Cancer Center), Anna C. Obenauf(Research Institute of Molecular Pathology), James A. Fagin(Memorial Sloan Kettering Cancer Center), Lu Wang(The Central Hospital of Xiao gan), Yu Chen(Guangdong Academy of Medical Sciences), William Lee(Drexel University), Devan Murphy(Memorial Sloan Kettering Cancer Center), Leili Ran(Memorial Sloan Kettering Cancer Center), Taha Merghoub(Cornell University)
Cited by 251
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k